In this analysis of patients with myeloperoxidase-ANCA-positive AAV, all urinary complement C3 fragment levels were elevated significantly compared with healthy controls (P .01 for all). Specific ...

Thank you, Eva, and thank you all for joining us this morning. Before turning to our fourth quarter results, I would like to ...

The fact that the complement system is activated during immune-complex glomerular disease has been known for nearly 50 years. Detection of complement deposition in the glomerulus using immunochemistry ...

Among the most serious consequences of diabetes mellitus is the development of diabetic angiopathy, of which the clinical features are cardiovascular disease, retinopathy, nephropathy and neuropathy.

Full-year 2025 net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® ...

Apellis Pharmaceuticals, Inc. ( APLS) TD Cowen 46th Annual Health Care Conference March 2, 2026 9:50 AM EST ...

Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 ...

Apellis Pharmaceuticals APLS reported fourth-quarter 2025 loss of 47 cents per share, wider than the Zacks Consensus Estimate ...

Quantum computers—devices that process information using quantum mechanical effects—have long been expected to outperform classical systems on certain tasks. Over the past few decades, researchers ...

Apellis Pharmaceuticals (NASDAQ:APLS) used its fourth-quarter and full-year 2025 earnings call to highlight what management ...

A complement C4 (also known as a complement component 4, or simply C4) is a test to measure the level of C4 proteins you have in your blood. These proteins play a role in how your immune system ...

Q3 FY2026 earnings call recap: weak sales, major restructuring (26% headcount cut), federal bookings strength, and FY guidance.